IndustryCompany release

Gossamer Bio files first NDA for seralutinib in PAH; $125M more in financing tied to FDA acceptance

🇺🇸 Gossamer Bio, Inc. (GOSS) · Tue 10 Nov 2026

Gossamer Bio reported Q3 2026 results on November 10, 2026, and said it submitted its first New Drug Application to the U.S. FDA in September 2026 for inhaled seralutinib in pulmonary arterial hypertension. The FDA has yet to decide whether to accept the filing. Acceptance in 2026 would unlock up to about $125 million of committed private placement capital. The company ended the quarter with $51.2 million in cash and securities after reacquiring worldwide rights from Chiesi and completing a 1-for-80 reverse split.

Company's press release (SEC filing): Gossamer Bio, Inc. ↗

Brief written by VigiEye from the company's press release filed with the SEC. Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →